SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Charlotte Brontë — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientCharlotte Brontë
Date of birth1816-04-21
IdentifiersMRN HR-NI025-SYN-TD; SSN (made up) 000-25-3804
Document date1855-03-24
AuthorEleanor Thwaite, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Prenatal visit at 17 weeks. [S]

History of Present Illness

Ms. Brontë returns at 17 weeks 1 day. She has not vomited for ten days and has needed no ondansetron for two weeks. Mild nausea comes on only when she is tired. She eats well and walks out most afternoons. She takes doxylamine-pyridoxine four tablets a day, aspirin 81 mg at bedtime without bruising or bleeding, and folic acid. Her PUQE-24 score is 4. She has no palpitations, headache, visual change, pain, bleeding, or urinary symptoms. She is writing most mornings and feels hopeful. [S]

ElementDetail
Interval changeNo vomiting for ten days; no ondansetron for two weeks
PUQE-244 (mild), down from 14 at its worst
MedicationsDoxylamine-pyridoxine four tablets a day, aspirin 81 mg, folic acid
MoodHopeful; EPDS 5

Review of Systems

SystemResultFinding
GastrointestinalNegativeNo vomiting; mild nausea only when tired; bowels regular
CardiovascularNegativeNo palpitations
NeurologicalNegativeNo headache or visual change
GenitourinaryNegativeNo bleeding or urinary symptoms
PsychiatricNegativeMood good; EPDS 5

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Folic acid 0.4 mg oral tablet, one tablet by mouth daily (replacing an iron-containing prenatal vitamin while nausea is severe)One tablet by mouth dailyOral route1855-01-13activeS
Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, two tablets by mouth at bedtimeTwo tablets by mouth at bedtimeOral route1855-01-13 to 1855-01-20completedS
Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, one tablet in the morning, one mid-afternoon, and two at bedtime (four a day)One tablet in the morning, one mid-afternoon, and two at bedtimeOral route1855-01-20activeS
Metoclopramide 10 mg oral tablet, one tablet by mouth three times a day before mealsOne tablet by mouth three times a day, 30 minutes before mealsOral route1855-01-20 to 1855-01-29completedS
Sodium chloride 0.9% with potassium chloride 20 mmol per liter, 1000 mL intravenously over 8 hours1000 mL over 8 hours, guided by daily electrolytesIntravenous route1855-01-29 to 1855-02-01completedS
Thiamine 100 mg intravenously daily, the first dose before any dextrose100 mg intravenously once daily; first dose before any dextrose-containing fluidIntravenous route1855-01-29 to 1855-02-01completedS
Ondansetron 4 mg intravenously every 8 hours4 mg by slow intravenous injection every 8 hoursIntravenous route1855-01-29 to 1855-02-01completedS
Enoxaparin 20 mg subcutaneously once daily during the admission (weight under 50 kg)20 mg (0.2 mL) subcutaneously once daily while in hospitalSubcutaneous route1855-01-29 to 1855-02-01completedS
Magnesium sulfate 2 g in 50 mL intravenously over 1 hour, once2 g intravenously over 1 hour, one doseIntravenous route1855-01-29 to 1855-01-29completedS
Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hoursOne tablet on the tongue every 8 hoursOral route1855-02-01 to 1855-02-24completedS
Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for nauseaOne tablet on the tongue up to every 8 hours if neededOral route1855-02-24 to 1855-03-24completedS
Thiamine 100 mg oral tablet, one tablet by mouth three times a dayOne tablet by mouth three times a day while intake is poorOral route1855-02-01 to 1855-02-24completedS
Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtimeOne tablet by mouth at bedtime until deliveryOral route1855-02-24activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1855-03-24Body height152cmS
1855-03-24Body weight46.2kgS
1855-03-24Body mass index (BMI) [Ratio]20kg/m2S
1855-03-24Systolic blood pressure108mm[Hg]S
1855-03-24Diastolic blood pressure68mm[Hg]S
1855-03-24Heart rate80/minS
1855-03-24Respiratory rate14/minS
1855-03-24Body temperature36.7CelS
1855-03-24Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1855-03-24Hemoglobin [Mass/volume] in Blood11.6g/dL11-15.5 g/dLNormalS
1855-03-24Thyrotropin [Units/volume] in Serum or Plasma0.92m[IU]/L0.2-3 mIU/LNormalS
1855-03-24Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.1ng/dL0.8-1.8 ng/dLNormalS
1855-03-24Total score [EPDS]5{score}S

Physical Exam

Vital signs recorded on 1855-03-24; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 46.2 kg
NeckThyroid not enlarged
AbdomenFundus midway between the pubic bone and the umbilicus
FetalFetal heart 150 per minute by Doppler

Problems

ProblemClinical statusVerificationCodeProvenance
First pregnancy at 38 (elderly primigravida), single live intrauterine pregnancy dated by ultrasound at 7 weeks 1 dayactiveconfirmed O09.519S — Synthetic modern prenatal care anchored to the documented report that she was pregnant when she died; the pregnancy itself is questioned in one source (CLM-0019).
Nausea and vomiting of pregnancy, moderate (PUQE-24 score 10), with early weight loss, under evaluation for hyperemesis gravidarumresolvedconfirmed O21.9S — Synthetic presenting concern at the index visit, superseded by the hyperemesis gravidarum diagnosis at the sick visit; her documented "perpetual nausea" is D and the hyperemesis reading of it is R.
Hyperemesis gravidarum with metabolic disturbance: unable to keep fluids down, 7.4 percent weight loss, dehydration, hypokalemia, hyponatremia, hypochloremic alkalosis, low magnesium, and raised transaminases; PUQE-24 score 14activeconfirmed O21.1S — Synthetic modern diagnosis linked to her documented final illness and the retrospective hyperemesis interpretation; it is not asserted as her historical diagnosis.
Gestational transient thyrotoxicosis: suppressed TSH and mildly raised free T4 with hyperemesis, no goiter, eye signs, or tremor; no treatment neededresolvedconfirmed O99.281S — Synthetic finding that teaches the thyroid tests in hyperemesis; it echoes no documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyPUQE-24 score (recorded in the note; no LOINC code found)Every visit while nausea and vomiting lastCompleted today4 (mild)
ExaminationWeight against pre-pregnancy weight (46.0 kg), pulse, blood pressure, and hydrationEvery visit while nausea and vomiting lastCompleted today46.2 kg, back above her pre-pregnancy weight; pulse 80
LaboratoryTSH and free T4In hyperemesis gravidarum; repeat at 16 to 18 weeks if suppressedCompleted todayTSH 0.92 mIU/L and free T4 1.1 ng/dL: normal
LaboratoryHemoglobinAt intake and again at 24 to 28 weeks; earlier after hemoconcentrationCompleted today11.6 g/dL
LaboratoryElectrolytes, urea nitrogen, creatinine, and glucoseUntil stable on oral intakeNot indicatedNot repeated: normal on oral intake
Medication safetyAntiemetic taperWhen vomiting has stopped for a weekCompleted todayOndansetron stopped; doxylamine-pyridoxine taper over two weeks
Medication safetyLow-dose aspirinEvery visitCompleted todayTaken nightly; no bruising or bleeding
SurveyPerinatal mood screenEach trimesterCompleted todayEPDS 5; item 10 scored 0
ImagingDetailed anatomy scanAt 18 to 22 weeksDueBooked for 20 weeks
ExaminationBlood pressureEvery prenatal visitCompleted today108/68 mmHg
ExaminationFetal heartEvery prenatal visitCompleted today150 per minute by Doppler

Goal progress:

Guideline basis: ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy (2018); The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69) (2024); Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication (2021); 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum (2017); Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum (Clinical Practice Guideline No. 4) (2023)

Follow-up: Anatomy scan in three weeks and prenatal visit in four weeks. [S]